Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02381314 | Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer | PHASE1 | COMPLETED | 24 | — | — | Mar 26, 2015 | Sep 26, 2018 | Feb 8, 2022 | 10 | United States |
Adverse events, serious adverse events
| Arm | Type | Description |
|---|---|---|
| enoblituzumab plus ipilimumab | EXPERIMENTAL | Enoblituzumab: Fc-optimized, humanized monoclonal antibody. Ipilimumab: Yervoy; recombinant, fully humanized IgG-1 CTLA-4 blocking antibody approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of unresectable or metastatic melanoma. |
| Name | Type | Description |
|---|---|---|
| enoblituzumab plus ipilimumab | BIOLOGICAL | enoblituzumab is administered by IV infusion once per week. Ipilimumab is administered by IV infusion every 3 weeks for up to 4 doses. |
Inclusion Criteria - Cohort Expansion Phase: * Histologically-proven, unresectable, locally advanced or metastatic melanoma or NSCLC * Melanoma: Advanced or metastatic melanoma patients may be systemic therapy naïve or may have received systemic treatment for unresectable locally advanced or met...